Resources

Selected
  • COVID-19
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

1589 results found

2023 ∙ Karofi, D. H. Lawal, N. Bello, M. B. Imam, M. U.

Immunogenicity and Protective Efficacy of Nucleic Acid-Based Vaccines Against COVID-19: A Systematic Review

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Katoto, P. D. Kakubu, M. A. Tamuzi, J. L. Brand, A. S. Ayuk, A. Byamungu, L. N. Wiysonge, C. S. Gray, G.

Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses

  • Adolescents
  • Adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2023 ∙ Li, P. Wang, W. Tao, Y. Tan, X. Li, Y. Mao, Y. Gao, L. Feng, L. Zhan, S. Sun, F.

Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis

  • Adults
  • COVID-19
  • Administration
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Cheng, M. Q. Li, R. Luo, X. Chen, J. Y. Bai, Z. P. Zhao, P. Weng, Z. Y. Song, G.

Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Zhao, T. Yang, Z. Wu, Y. Yang, J.

Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2023 ∙ Vasconcelos, Z. S. Salem, H. A. Veiga, S. P. Lima, F. E. B. Gonçalves, Crds Santos, E. C. D. Brandão, A. R. J. Couceiro, K. N. Guerra, J. A. O. Guerra, Mdgvb

Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Al-Haideri, M. Mohammad, T. A. M. Darvishzadehdeldari, S. Karbasi, Z. Alimohammadi, M. Faramarzi, F. Khorasani, S. Rasouli, A. Tahmasebi, S. Darvishi, M. Akhavan-Sigari, R.

Immunogenicity of COVID-19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Griffin, D. W. Pai Mangalore, R. Hoy, J. F. McMahon, J. H.

Immunogenicity, effectiveness and safety of SARS-CoV-2 vaccination in people living with HIV: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Gao, P. Kang, L. Y. Liu, J. Liu, M.

Immunogenicity, effectiveness, and safety of COVID-19 vaccines among children and adolescents aged 2-18 years: an updated systematic review and meta-analysis

  • Children
  • Adolescents
  • COVID-19
  • Administration
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Griffin, D. W. J. Pai Mangalore, R. Hoy, J. F. McMahon, J. H.

Immunogenicity, effectiveness, and safety of SARS-CoV-2 vaccination in people with HIV

  • Adults
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
Loading...